A common hematological complication associated with luminal GI cancers both at diagnosis and during treatment is anemia, defined by the World Health Organization (WHO) as hemoglobin (Hb) of less than 12 g/dL in women, and less than 13 g/dL in men [2, 3]. This evidence concerns the gene GSTM1 and anemia (phenotype).